prepared by the American Medical Association Department of Drugs, Division of Drugs and Technology, ed 6; 1654 pp, with illus, $75, Chicago, American Medical Association, 1986.
This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
AMA Drug Evaluations has been issued every two to four years since 1971 and is intended to provide health professionals with up-to-date, unbiased information on the clinical use of drugs. It serves a role quite different from that of a book like Goodman and Gilman. The latter is encyclopedic, while Drug Evaluations aims to provide a distilled, more practical therapeutic message. Many people are involved in its production: American Medical Association staff, medical staff of pharmaceutical companies, and 512 consultants chosen by the American Society for Clinical Pharmacology and Therapeutics.
Unrestrained by Food and Drug Administration—approved labeling (as it should be!), the volume recognizes the legitimate use of drugs regardless of their regulatory status and even includes drugs not as yet available on the US market.
Reviewing a tome of this size in such a way as to do it justice is always a challenge. One ends up dipping into
Lasagna L. Drug Evaluations. JAMA. 1987;257(17):2363-2364. doi:10.1001/jama.1987.03390170119045